225 related articles for article (PubMed ID: 28386258)
1. Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.
Clemente N; Comi C; Raineri D; Cappellano G; Vecchio D; Orilieri E; Gigliotti CL; Boggio E; Dianzani C; Sorosina M; Martinelli-Boneschi F; Caldano M; Bertolotto A; Ambrogio L; Sblattero D; Cena T; Leone M; Dianzani U; Chiocchetti A
Front Immunol; 2017; 8():321. PubMed ID: 28386258
[TBL] [Abstract][Full Text] [Related]
2. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis.
Murugaiyan G; Mittal A; Weiner HL
J Immunol; 2008 Dec; 181(11):7480-8. PubMed ID: 19017937
[TBL] [Abstract][Full Text] [Related]
3. The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS).
Braitch M; Constantinescu CS
Inflamm Allergy Drug Targets; 2010 Sep; 9(4):249-56. PubMed ID: 20887272
[TBL] [Abstract][Full Text] [Related]
4. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS.
Chen M; Chen G; Nie H; Zhang X; Niu X; Zang YC; Skinner SM; Zhang JZ; Killian JM; Hong J
Eur J Immunol; 2009 Sep; 39(9):2525-36. PubMed ID: 19670379
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis.
Cappellano G; Woldetsadik AD; Orilieri E; Shivakumar Y; Rizzi M; Carniato F; Gigliotti CL; Boggio E; Clemente N; Comi C; Dianzani C; Boldorini R; Chiocchetti A; Renò F; Dianzani U
Vaccine; 2014 Sep; 32(43):5681-9. PubMed ID: 25149432
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin expression and the effect of anti-VLA-4 mAb treatment in experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis.
Pyka-Fościak G; Litwin JA; Lis GJ
Folia Neuropathol; 2023; 61(2):129-137. PubMed ID: 37587887
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin-metallothionein I/II interactions in experimental autoimmune encephalomyelitis.
Jakovac H; Grubić Kezele T; Šućurović S; Mulac-Jeričević B; Radošević-Stašić B
Neuroscience; 2017 May; 350():133-145. PubMed ID: 28344072
[TBL] [Abstract][Full Text] [Related]
8. Myelin oligodendrocyte glycoprotein induces aquaporin-4 autoantibodies in mouse experimental autoimmune encephalomyelitis.
Wu X; Zhou M; Ding H; Xu S; Wang C; Chan P
J Neuroimmunol; 2013 Aug; 261(1-2):1-6. PubMed ID: 23707078
[TBL] [Abstract][Full Text] [Related]
9. T cell and antibody responses in remitting-relapsing experimental autoimmune encephalomyelitis in (C57BL/6 x SJL) F1 mice.
Zhang GX; Yu S; Gran B; Li J; Calida D; Ventura E; Chen X; Rostami A
J Neuroimmunol; 2004 Mar; 148(1-2):1-10. PubMed ID: 14975581
[TBL] [Abstract][Full Text] [Related]
10. Lentivirus-mediated estrogen receptor α overexpression in the central nervous system ameliorates experimental autoimmune encephalomyelitis in mice.
Hu X; Qin X
Int J Mol Med; 2013 May; 31(5):1209-21. PubMed ID: 23525227
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE.
Skundric DS; Dai R; Zakarian VL; Bessert D; Skoff RP; Cruikshank WW; Kurjakovic Z
J Neurosci Res; 2005 Mar; 79(5):680-93. PubMed ID: 15682385
[TBL] [Abstract][Full Text] [Related]
12. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.
Ingwersen J; Wingerath B; Graf J; Lepka K; Hofrichter M; Schröter F; Wedekind F; Bauer A; Schrader J; Hartung HP; Prozorovski T; Aktas O
J Neuroinflammation; 2016 Feb; 13():48. PubMed ID: 26920550
[TBL] [Abstract][Full Text] [Related]
13. Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice.
Berard JL; Wolak K; Fournier S; David S
Glia; 2010 Mar; 58(4):434-45. PubMed ID: 19780195
[TBL] [Abstract][Full Text] [Related]
14. Cytokine production profiles in chronic relapsing-remitting experimental autoimmune encephalomyelitis: IFN-γ and TNF-α are important participants in the first attack but not in the relapse.
Hidaka Y; Inaba Y; Matsuda K; Itoh M; Kaneyama T; Nakazawa Y; Koh CS; Ichikawa M
J Neurol Sci; 2014 May; 340(1-2):117-22. PubMed ID: 24655735
[TBL] [Abstract][Full Text] [Related]
15. Plasma osteopontin levels in multiple sclerosis.
Comabella M; Pericot I; Goertsches R; Nos C; Castillo M; Blas Navarro J; Río J; Montalban X
J Neuroimmunol; 2005 Jan; 158(1-2):231-9. PubMed ID: 15589058
[TBL] [Abstract][Full Text] [Related]
16. Converting relapsing remitting to secondary progressive experimental allergic encephalomyelitis (EAE) by ultraviolet B irradiation.
Tsunoda I; Kuang LQ; Igenge IZ; Fujinami RS
J Neuroimmunol; 2005 Mar; 160(1-2):122-34. PubMed ID: 15710465
[TBL] [Abstract][Full Text] [Related]
17. Human amniotic epithelial cells suppress relapse of corticosteroid-remitted experimental autoimmune disease.
Liu YH; Chan J; Vaghjiani V; Murthi P; Manuelpillai U; Toh BH
Cytotherapy; 2014 Apr; 16(4):535-44. PubMed ID: 24411589
[TBL] [Abstract][Full Text] [Related]
18. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease.
Chabas D; Baranzini SE; Mitchell D; Bernard CC; Rittling SR; Denhardt DT; Sobel RA; Lock C; Karpuj M; Pedotti R; Heller R; Oksenberg JR; Steinman L
Science; 2001 Nov; 294(5547):1731-5. PubMed ID: 11721059
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods.
Khan N; Woodruff TM; Smith MT
Pharmacol Biochem Behav; 2014 Nov; 126():13-27. PubMed ID: 25223977
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response.
Matsushita T; Fujimoto M; Hasegawa M; Komura K; Takehara K; Tedder TF; Sato S
Am J Pathol; 2006 Mar; 168(3):812-21. PubMed ID: 16507897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
